Detalhe da pesquisa
1.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709073
2.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
3.
Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ther Innov Regul Sci
; 57(4): 899-910, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37179264
4.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Hemasphere
; 7(11): e966, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37901848
5.
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
BMC Cancer
; 12: 415, 2012 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22992303
6.
Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials.
Ther Innov Regul Sci
; 56(4): 552-560, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35503503
7.
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Clin Lymphoma Myeloma Leuk
; 20(1): e30-e37, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31780415
8.
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Blood Adv
; 2(13): 1633-1644, 2018 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29991494
9.
Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status.
Stroke
; 37(6): 1385-90, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16675738
10.
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 15(11): 680-6, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26482107
11.
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Eur J Cancer
; 49(2): 312-22, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22954665
12.
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Clin Cancer Res
; 19(10): 2745-54, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23444220
13.
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
J Clin Oncol
; 30(13): 1484-91, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22412143
14.
Making sense of DNA microarray data.
Methods Mol Med
; 113: 293-304, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15968112